Nov 14 (Reuters) - German drugmaker Evotec EVTG.DE is attracting takeover interest from U.S.-based Halozyme Therapeutics HALO.O, Bloomberg News reported on Thursday.
Halozyme has recently expressed interest in acquiring Evotec at about 11 euros per share, the report added, citing people familiar with the matter.
Earlier this week private equity firm Triton was also reportedly exploring a potential buyout of Evotec, after it confirmed a close to 10% stake in the company.
Evotec's other major shareholders are Novo Nordisk NOVOb.CO parent Novo Holdings and Mubadala Investment.
Evotec's shares have fallen about 60% this year as revenues continue to slump due to weakness in the clinical research organization business market environment.
The company collaborates with biotech companies through research alliances and development partnerships to help with drug development.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
((Christy.Santhosh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.